CINECA IRIS Institutional Research Information System
IRIS è l'Anagrafe della ricerca dell'Università degli Studi di Trento, e ha lo scopo di raccogliere, documentare, conservare e diffondere, anche ad accesso aperto, la produzione scientifica degli autori afferenti all'Università degli Studi di Trento.
EnglishThe availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.
Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? / Caffo, Orazio; Lunardi, Andrea; Trentin, Chiara; Veccia, Antonello; Galligioni, Enzo. - In: CURRENT DRUG TARGETS. - ISSN 1873-5592. - 2016(2016).
Scheda prodotto non validato
I dati visualizzati non sono stati ancora sottoposti a validazione formale da parte dello Staff di IRIS, ma sono stati ugualmente trasmessi al Sito Docente Cineca (Loginmiur).
| Titolo: | Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? |
| Autori: | Caffo, Orazio; Lunardi, Andrea; Trentin, Chiara; Veccia, Antonello; Galligioni, Enzo |
| Autori Unitn: | |
| Titolo del periodico: | CURRENT DRUG TARGETS |
| Anno di pubblicazione: | 2016 |
| Codice identificativo Scopus: | 2-s2.0-84983749203 |
| Codice identificativo Pubmed: | 26721408 |
| Codice identificativo ISI: | WOS:000387064500010 |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.2174/1389450117666160101121317 |
| Handle: | http://hdl.handle.net/11572/128193 |
| Citazione: | Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? / Caffo, Orazio; Lunardi, Andrea; Trentin, Chiara; Veccia, Antonello; Galligioni, Enzo. - In: CURRENT DRUG TARGETS. - ISSN 1873-5592. - 2016(2016). |
| Appare nelle tipologie: | 03.1 Articolo su rivista (Journal article) |
File in questo prodotto:
Copyright © 2020